Parathyroid Hormone Related Protein in Hypercalcemia Malignancies
DOI:
https://doi.org/10.21467/preprints.592Abstract
Background: Paraneoplastic syndromes encompass symptoms or signs caused by malignant tumors through humoral factors, such as hormones or cytokines, produced by tumor cells. Hypercalcemia is a common occurrence in cancer patients, particularly associated with Parathyroid Hormone-related Protein (PTHrP). PTHrP mimics parathyroid hormone (PTH) activity, leading to excessive bone resorption, hypocalcemia, and significant metabolic complications.
Discussion: PTHrP plays a key role in malignancy-associated hypercalcemia, which is more acute and severe compared to primary hyperparathyroidism. PTHrP is produced by various tumors, including squamous cell carcinomas and breast adenocarcinomas, as well as some hematologic malignancies. Beyond its extracellular role in bone resorption, PTHrP also exerts intracellular effects through nuclear activities, influencing cell proliferation and apoptosis. Management of hypercalcemia prioritizes patient hydration, bisphosphonate use, and targeted therapies to mitigate PTHrP effects. Emerging treatments, such as monoclonal antibodies against PTHrP and osteoprotegerin, show potential for rapid calcium control.
Conclusion: PTHrP is a critical biomarker in malignancy-associated hypercalcemia, reflecting its central role in calcium metabolism regulation and as a promising target for innovative therapies. Prompt management of this condition can enhance patients' quality of life and reduce the risk of severe complications.
Keywords:
paraneoplastic syndrome, hypercalcemia, parathyroid hormone related proteinDownloads
References
Henry K. Paraneoplastic syndromes: Definitions, classification, pathophysiology and principles of treatment. Semin Diagn Pathol. 2019;36(4):204–210. doi:https://doi.org/10.1053/j.semdp.2019.01.002
Robbins SL; Kumar VK. Neoplasia. Elsevier Saunders; 2013.
Lancaster E. Paraneoplastic Disorders. Continuum (N Y). 2017;23(6):1653–1679.
Chan AM, Baehring JM. Paraneoplastic neurological syndromes: a single institution 10-year case series. J Neurooncol. 2019;141(2):431–439. doi:10.1007/s11060-018-03053-3
Loscalzo J, Fauci A, Kasper D, Hauser S, Longo D, Jameson J. eds. Harrison's Principles of Internal Medicine, 21e. McGraw-Hill Education; 2022.
Donovan PJ, Achong N, Griffin K, Galligan J, Pretorius CJ, McLeod DSA. PTHrP-Mediated Hypercalcemia: Causes and Survival in 138 Patients. J Clin Endocrinol Metab. 2015;100(5):2024–2029. doi:10.1210/jc.2014-4250
Moe SM. Disorders Involving Calcium, Phosphorus, and Magnesium. Prim Care Clin Off Pract. 2008;35(2):215–237. doi:https://doi.org/10.1016/j.pop.2008.01.007
Tinawi M. Disorders of Calcium Metabolism: Hypocalcemia and Hypercalcemia. Cureus. 2021;13(1):e12420. doi:10.7759/cureus.12420
Asonitis N, Angelousi A, Zafeiris C, Lambrou GI, Dontas I, Kassi E. Diagnosis, Pathophysiology and Management of Hypercalcemia in Malignancy: A Review of the Literature. Horm Metab Res = Horm und Stoffwechselforsch = Horm Metab. 2019;51(12):770–778. doi:10.1055/a-1049-0647
Goltzman D. Nonparathyroid hypercalcemia. Parathyr Disord. 2019;51:77–90.
In: Loscalzo J, Fauci A, Kasper D, Hauser S, Longo D, Jameson J. eds. Harrison's Principles of Internal Medicine, 21e. McGraw-Hill Education; 2022.
Hoftberger R; Rosenfeld MR; Dalmau J. Update on Neurological Paraneoplastic Syndromes. Curr Opin Oncol. 2015;27(6):489–495.
Horn L; Araujo L; Nana P; et al. Principles and Practice of Oncology. McGraw-Hill Education; 2015.
Gade AK, Olariu E, Douthit NT. Carcinoid Syndrome: A Review. Cureus. 2020;12(3):e7186. doi:10.7759/cureus.7186
Kanaji N, Watanabe N, Kita N, et al. Paraneoplastic syndromes associated with lung cancer. World J Clin Oncol. 2014;5(3):197–223.
Dimitriadis GK, Angelousi A, Weickert MO, et al. Paraneoplastic endocrine syndromes. Soc Endocrinol. 2017;24(6):173–190.
van Sonderen A, Wirtz PW, Verschuuren JJGM, Titulaer MJ. Paraneoplastic syndromes of the neuromuscular junction: therapeutic options in myasthenia gravis, lambert-eaton myasthenic syndrome, and neuromyotonia. Curr Treat Options Neurol. 2013;15(2):224–239. doi:10.1007/s11940-012-0213-6
Molitch ME. Diagnosis and Treatment of Pituitary Adenomas: A Review. JAMA. 2017;317(5):516–524. doi:10.1001/jama.2016.19699
Yasir M, Mechanic OJ. Syndrome of Inappropriate Antidiuretic Hormone Secretion. StatPearls Publ. Published online 2020. https://www.ncbi.nlm.nih.gov/books/NBK507777/
Wysolmerski JJ. Parathyroid hormone-related protein: an update. J Clin Endocrinol Metab. 2012;97(9):2947–2956. doi:10.1210/jc.2012-2142
Bodnar TW, Acevedo MJ, Pietropaolo M. Management of non-islet-cell tumor hypoglycemia: a clinical review. J Clin Endocrinol Metab. 2014;99(3):713–722. doi:10.1210/jc.2013-3382
Mulatero P, Rabbia F, Veglio F. Paraneoplastic hyperaldosteronism associated with non-Hodgkin’s lymphoma. N Engl J Med. 2001;344(20):1558–1559. doi:10.1056/NEJM200105173442017
Khan F, Kleppel H, Meara A. Paraneoplastic Musculoskeletal Syndromes. Rheum Dis Clin North Am. 2020;46(3):577–586. doi:10.1016/j.rdc.2020.04.002
Downloads
Posted
Section
Categories
License
Copyright (c) 2024 Fadel Fikri Suharto, Yenny Dian Andayani
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Any non-commercial use, distribution, adaptation, and reproduction in any medium is permitted as long as the original work is properly cited. However, caution and responsibility are required when reusing as the articles on the preprint server are not peer-reviewed. Readers are advised to check for the availability of any updated or peer-reviewed version.